Quoted Micro 2 June 2025

AQUIS STOCK EXCHANGE Probiotic ingredients developer ProBiotix Health (PBX) reported that it had a strong first quarter in 2026 with growth of 50%. This was at the same time as reporting a 13% increase in 2024 sales to £1.883m. Gross margins are more than 50%. There is £1.65m in the bank after a cash outflow […]

Quoted Micro 26 May 2025

AQUIS STOCK EXCHANGE Arbuthnot Banking Group (ARBB) stated at the AGM that trading was in line with expectations in the first four months of the year. Activity is showing signs of picking up. There were loan and lease assts of £2.36bn at the end of April 2025. Deposits rose 3% to £4.26bn. There was an […]

Quoted Micro 6 January 2025

AQUIS STOCK EXCHANGE Global Connectivity (GCON) is investing £50,000 in PLUG Group, which is a 4% stake. PLUG is developing opportunities to extract decommissioned copper cables for South American telecoms companies. Livia Meyer has returned 32.5 million shares and paid £50,000 for the other five million shares subscribed for. Executive chairman Dr Keith Harris has […]

Poolbeg Pharma #POLB – CEO Jeremy Skillington talks to Alan Green

Poolbeg Pharma CEO Jeremy Skillington talks to Alan Green, and recaps on the developments at the company since last year. These include the strategic collaboration with a Nasdaq-Listed Biopharma Co to use Poolbeg’s oral delivery technology, the expansion of Poolbeg’s IP, and the appointment t of a number of key former Amryt Pharma executives, namely […]

Poolbeg Pharma #POLB August 2023 – CEO Jeremy Skillington talks to Alan Green

Poolbeg CEO Jeremy Skillington talks to Alan Green in this August 2023 interview, and explains the company’s ‘capital light’ model that is giving the group a real market advantage. Jeremy then covers the developments this year with Poolbeg’s flagship POLB001 asset towards a blockbuster treatment for severe influenza, and the expansion of application into oncology […]